Compare BHFAN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Brighthouse Financial Inc. Depositary shares each representing a 1/1000th interest in a share of 5.375% Non-Cumulative Preferred Stock Series C
Current Price
| Metric | BHFAN | RLAY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | BHFAN | RLAY |
|---|---|---|
| Price | $12.89 | $10.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 89.3K | ★ 2.3M |
| Earning Date | N/A | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $396.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $11.51 | $1.78 |
| 52 Week High | $17.40 | $11.43 |
| Indicator | BHFAN | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 60.91 |
| Support Level | $12.32 | $9.06 |
| Resistance Level | $13.98 | $11.43 |
| Average True Range (ATR) | 0.20 | 0.77 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 2.56 | 56.56 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).